Stephen N Birrell MD PhD FRACS
Stephen N Birrell MD PhD FRACS
HAVAH Therapeutics
Verified email at havahtx.com - Homepage
Title
Cited by
Cited by
Year
Letrozole therapy alone or in sequence with tamoxifen in women with breast cancer
BIG 1-98 Collaborative Group
New England Journal of Medicine 361 (8), 766-776, 2009
5682009
Progesterone receptor modulates ERα action in breast cancer
H Mohammed, IA Russell, R Stark, OM Rueda, TE Hickey, GA Tarulli, ...
Nature 523 (7560), 313-317, 2015
5292015
Prognostic and predictive value of centrally reviewed expression of estrogen and progesterone receptors in a randomized trial comparing letrozole and tamoxifen adjuvant therapy …
G Viale, MM Regan, E Maiorano, MG Mastropasqua, P Dell'Orto, ...
Journal of Clinical Oncology 25 (25), 3846-3852, 2007
4682007
Assessment of letrozole and tamoxifen alone and in sequence for postmenopausal women with steroid hormone receptor-positive breast cancer: the BIG 1-98 randomised clinical …
MM Regan, P Neven, A Giobbie-Hurder, A Goldhirsch, B Ejlertsen, ...
The lancet oncology 12 (12), 1101-1108, 2011
3932011
Tamoxifen for prevention of breast cancer: extended long-term follow-up of the IBIS-I breast cancer prevention trial
J Cuzick, I Sestak, S Cawthorn, H Hamed, K Holli, A Howell, JF Forbes, ...
The lancet oncology 16 (1), 67-75, 2015
3842015
Androgen receptor inhibits estrogen receptor-α activity and is prognostic in breast cancer
AA Peters, G Buchanan, C Ricciardelli, T Bianco-Miotto, MM Centenera, ...
Cancer research 69 (15), 6131-6140, 2009
3802009
Prognostic and predictive value of centrally reviewed Ki-67 labeling index in postmenopausal women with endocrine-responsive breast cancer: results from Breast International …
G Viale, A Giobbie-Hurder, MM Regan, AS Coates, MG Mastropasqua, ...
Journal of clinical oncology 26 (34), 5569, 2008
3522008
Body mass index as a prognostic feature in operable breast cancer: the International Breast Cancer Study Group experience
G Berclaz, S Li, KN Price, AS Coates, M Castiglione-Gertsch, ...
Annals of Oncology 15 (6), 875-884, 2004
3162004
Androgens induce divergent proliferative responses in human breast cancer cell lines
SN Birrell, JM Bentel, TE Hickey, C Ricciardelli, MA Weger, DJ Horsfall, ...
The Journal of steroid biochemistry and molecular biology 52 (5), 459-467, 1995
2951995
Risk factors for locoregional recurrence among breast cancer patients: results from International Breast Cancer Study Group Trials I through VII
A Wallgren, M Bonetti, RD Gelber, A Goldhirsch, M Castiglione-Gertsch, ...
Journal of Clinical Oncology 21 (7), 1205-1213, 2003
2872003
Breast and prostate cancer: more similar than different
GP Risbridger, ID Davis, SN Birrell, WD Tilley
Nature Reviews Cancer 10 (3), 205-212, 2010
2502010
Letrozole compared with tamoxifen for elderly patients with endocrine-responsive early breast cancer: the BIG 1-98 trial
D Crivellari, Z Sun, AS Coates, KN Price, B Thürlimann, H Mouridsen, ...
Journal of clinical oncology 26 (12), 1972-1979, 2008
1632008
Role of the androgen receptor in human breast cancer
SN Birrell, RE Hall, WD Tilley
Journal of mammary gland biology and neoplasia 3 (1), 95-103, 1998
1601998
Bone fractures among postmenopausal patients with endocrine-responsive early breast cancer treated with 5 years of letrozole or tamoxifen in the BIG 1-98 trial
M Rabaglio, Z Sun, KN Price, M Castiglione-Gertsch, H Hawle, ...
Annals of oncology 20 (9), 1489-1498, 2009
1592009
Androgen receptor agonist activity of the synthetic progestin, medroxyprogesterone acetate, in human breast cancer cells
JM Bentel, SN Birrell, MA Pickering, DJ Holds, DJ Horsfall, WD Tilley
Molecular and cellular endocrinology 154 (1-2), 11-20, 1999
1261999
BIG 1–98: Randomized double-blind phase III study to evaluate letrozole (L) vs. tamoxifen (T) as adjuvant endocrine therapy for postmenopausal women with receptor-positive …
BJ Thurlimann, A Keshaviah, H Mouridsen, L Mauriac, JF Forbes, ...
Journal of Clinical Oncology 23 (16_suppl), 511-511, 2005
1252005
Swipe imager with multiple sensing arrays
L Hamid, SN Ashdown
US Patent 7,043,061, 2006
1032006
Disruption of androgen receptor signaling by synthetic progestins may increase risk of developing breast cancer
SN Birrell, LM Butler, JM Harris, G Buchanan, WD Tilley
The FASEB Journal 21 (10), 2285-2293, 2007
1022007
MDA-MB-453, an androgen-responsive human breast carcinoma cell line with high level androgen receptor expression
RE Hall, SN Birrell, WD Tilley, RL Sutherland
European journal of cancer 30 (4), 484-490, 1994
981994
Medroxyprogesterone acetate therapy in advanced breast cancer: the predictive value of androgen receptor expression.
SN Birrell, DM Roder, DJ Horsfall, JM Bentel, WD Tilley
Journal of clinical oncology 13 (7), 1572-1577, 1995
951995
The system can't perform the operation now. Try again later.
Articles 1–20